OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Stock Short Interest Report for October

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 76,652 shares, a growth of 121.3% from the September 30th total of 34,643 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 42,929 shares, the short-interest ratio is currently 1.8 days.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on OKYO shares. HC Wainwright restated a “buy” rating on shares of OKYO Pharma in a research note on Wednesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a report on Thursday, October 15th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, OKYO Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $5.67.

OKYO Pharma Stock Down 3.3%

Shares of NASDAQ:OKYO traded down $0.05 during trading on Friday, hitting $1.45. 97,439 shares of the company were exchanged, compared to its average volume of 136,501. The business’s 50 day moving average is $1.44 and its 200-day moving average is $1.64. OKYO Pharma has a 1-year low of $1.26 and a 1-year high of $3.20.

Hedge Funds Weigh In On OKYO Pharma

A hedge fund recently bought a new position in OKYO Pharma stock. Opaleye Management Inc. acquired a new position in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 375,204 shares of the company’s stock, valued at approximately $563,000. Opaleye Management Inc. owned 0.71% of OKYO Pharma as of its most recent filing with the Securities and Exchange Commission. 2.97% of the stock is currently owned by institutional investors and hedge funds.

About OKYO Pharma

OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for inflammatory, ocular and pain-related diseases. The company’s research is centered on G protein-coupled receptors (GPCRs), a broad class of biological targets involved in regulating immune responses, pain signaling and other disease processes.

OKYO’s lead development program, OK-101, is a novel GPCR-targeting therapeutic being investigated for conditions including dry eye disease and neuropathic pain.